The authors of this case–control study compared the ThyroSeq genetic profiles of 62 patients with differentiated thyroid cancer with distant metastasis to a propensity-matched cohort without metastatic disease after over 5 years of follow-up. A TERT, TP53, or PIK3CA mutation was found in two-thirds of patients in the cohort with distant metastatic disease. The high-risk […]
In this ancillary analysis of the RTOG 9601 study, the researchers validated a 22-gene genomic classifier panel as a predictive biomarker for distant metastases in men with recurrent prostate cancer after radical prostatectomy. The final cohort included 352 men, 89.2% of whom were white. Genomic classifier scores in the final cohort were found to be
VALIDATION OF A 22-GENE GENOMIC CLASSIFIER IN PATIENTS WITH RECURRENT PROSTATE CANCER Read More »
Deletion of the long arm of chromosome 6 (del6q) is the most frequent cytogenetic abnormality in Waldenström macroglobulinaemia (WM), occurring in approximately 50% of patients. Its effect on patient outcome has not been completely established. In this study, they used fluorescence in situ hybridisation (FISH) to analyse the prevalence of del6q in selected CD19+ bone
On January 15, 2021, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo) for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. Efficacy was evaluated in a multicenter, open-label, randomized trial (DESTINY-Gastric01, NCT03329690) in patients with HER2-positive locally advanced or metastatic
FDA APPROVES FAM-TRASTUZUMAB DERUXTECAN-NXKI FOR HER2-POSITIVE GASTRIC ADENOCARCINOMAS Read More »
In a study published online in The New England Journal of Medicine, Alice T. Shaw and coauthors presented the results of CROWN, a phase III trial evaluating the third-generation tyrosine kinase inhibitor (TKI) lorlatinib in patients with advanced non–small cell lung cancer (NSCLC) harboring an ALK translocation. ALK translocation and mutations occur in 2% to 7%
FIRST-LINE LORLATINIB OR CRIZOTINIB IN ADVANCED ALK-POSITIVE LUNG CANCER Read More »
The authors of this phase Ib trial evaluated the oral IDH1 inhibitor ivosidenib in combination with azacitidine in 23 patients with newly diagnosed acute myeloid leukemia ineligible for intensive induction chemotherapy. The overall and complete response rates were 78% and 61%, respectively. The median duration of response and median overall survival were not yet reached
The authors of this phase II trial evaluated the PARP inhibitor olaparib in the treatment of 54 patients with metastatic breast cancer (76% ER-positive/HER2-negative) and either germline mutations in non-BRCA1/2 homologous recombination–related DNA repair genes (cohort 1) or somatic mutations in BRCA1/2 or other non-BRCA1/2 homologous recombination–related genes (cohort 2). The objective response rate (ORR)
The U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (Combined Positive Score [CPS] ≥10). “Approximately 15-20% of patients with breast cancer are diagnosed with triple-negative breast cancer, which
The authors report the 5-year outcomes of this multicenter, double-blind, phase III study of nivolumab versus dacarbazine for the first-line treatment of 418 patients with unresectable stage III/IV, wild-type BRAF melanoma. Benefits for overall survival, progression-free survival, and objective response rate with nivolumab were confirmed. The 5-year overall survival rate was 39% with nivolumab. Among
FIVE-YEAR OUTCOMES WITH NIVOLUMAB IN PATIENTS WITH WILD-TYPE BRAF ADVANCED MELANOMA Read More »
The authors of this review and meta-analysis of phase III trials evaluated the use of daratumumab for the treatment of newly diagnosed and relapsed/refractory multiple myeloma. While the individual trials did not demonstrate a statistically significant survival benefit, the meta-analysis did showed improvement in both progression-free and overall survival with daratumumab for both standard-risk and
